对于NMOSD灾难性复发的eculizumab:病例报告
David Gorriz1, Francisco Carlos Pérez-Miralles2, Carlos Quintanilla-Bordás2
1Neuroinmunology Unit, Neurology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain. gorriz_dav@gva.es.
概括
这份病例报告强调了一名患有严重神经omyelitis光学谱障碍 (NMOSD) 的患者,在传统治疗失败后,他对eculizumab产生了积极反应. 该研究还讨论了可溶性神经纤维光链 (sNfL) 在NMOSD管理中的作用.
科学领域:
- 神经免疫学 神经免疫学
- 中枢神经系统炎症性疾病 中枢神经系统炎症性疾病
背景情况:
- 神经omyelitis光谱障碍 (NMOSD) 涉及中枢神经系统的免疫媒介脱髓和轴突损伤,主要影响脊髓和视神经.
- 血清阳性NMOSD,特别是攻击性形式,带来了重大治疗挑战.
研究的目的:
- 报告一个对常规疗法耐药的积极的,阳性NMOSD病例.
- 为了说明eculizumab在危及生命的NMOSD复发中的有效性.
- 讨论可溶性神经纤维光链 (sNfL) 作为生物标志物的潜在作用.
主要方法:
- 一个47岁的女性患者的病例报告,患有血清阳性NMOSD.
- 综述治疗史,包括皮质类固醇,血交换和环胺.
- 在严重复发期间观察对eculizumab治疗的反应.
主要成果:
- 患者经历了危及生命的复发,对标准治疗没有反应.
- 埃奎利祖马布的使用导致了积极的临床反应,表明其在耐火性NMOSD中的有效性.
- 还描述了可溶性神经纤维光链 (sNfL) 的水平及其作用.
结论:
- 埃奎利祖马布代表了对侵袭性,耐治疗性NMOSD的可行和有效的治疗选择.
- 对sNfL等生物标志物在NMOSD中的作用进行进一步的研究是有必要的,以改善患者管理和监测.
更多相关视频
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.7K
09:41Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
Published on: January 20, 2023
1.9K
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Antiepileptic Drugs: Potassium Channel Activators
214
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
214
